The KI at The Leading-edge of Nanomedicine
The nanotechnology-based drug delivery systems being developed at the KI are a revolutionary gateway to new, more targeted disease treatments. An MIT News article published on March 11 nicely featured the exciting work of KI members Dan Anderson, Paula Hammond, Michael Cima, and Robert Langer, who are engineering new nanoscale therapeutic agents that selectively target and destroy cancer cells or help monitor tumor response to treatment. “We’re doing this because we can do some cool technology, but more importantly, we’re doing it because there’s a clinically meaningful need,” says Cima.
more...
